Recent Updates
Recently added Catalysts
IRIX Positive Sentiment Score: 70/100

Iridex to Present at the Sidoti Year-End Virtual Investor Conference

Key Takeaway: Iridex Corporation has announced its participation in the Sidoti Year-End Virtual Investor Conference scheduled for December 11, 2025. During this event, management will present at 10:45 am ET, and interested parties will be able to access both live and archived webcasts via the company’s website. Iridex is noted for its advanced laser-based medical systems, particularly for treating glaucoma and retinal diseases, showcasing its position in the ophthalmology market.

Market Sentiment Analysis

POSITIVE FACTORS

  • Iridex is a leader in innovative medical laser systems.
  • The company is actively engaging with investors through presentations.
  • Their technology offers effective treatments for serious eye conditions.

Full Press Release Details

MOUNTAIN VIEW, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming Sidoti Year-End Virtual Investor Conference.
Management is scheduled to present on Thursday, December 11 at 10:45 am ET. Interested parties may access a live and archived webcast of the presentation on the “Event Calendar” page of the “Investors” section of the company’s website at www.IRIDEX.com.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Investor Relations Contact
For more information about Iridex technologies, visit www.iridex.com.

Frequently Asked Questions

When is Iridex presenting at the Sidoti Conference?

Iridex will present on December 11 at 10:45 am ET.

How can I access Iridex's conference presentation?

You can access the live and archived webcast on their website's Event Calendar.

What technologies does Iridex specialize in?

Iridex specializes in laser-based medical systems for glaucoma and retinal diseases.

What is MicroPulse® technology?

MicroPulse® technology allows effective laser treatment while reducing tissue damage.

Where does Iridex sell its products?

Iridex sells its products in over 100 countries through direct sales and distributors.

Last updated: Dec 5, 2025